Introduction. Previous studies described that COVID-19 disease has considerable effects on the musculoskeletal system, causing excessive fatigue, myalgia, arthralgia, muscle weakness, and skeletal muscle damage. These symptoms can persist for months, decreasing the quality of life of numerous individuals. Objectives. Study of the pattern of rheumatic and musculoskeletal diseases (RMD) following COVID-19 disease. Material and methods. We performed an observational study of a group of adult patients with a new diagnosis of RMD in a time interval of 12 months after COVID-19 diagnosis. Results. The study included 47 patients (mean age 45.5±11.3 years, M: F ratio 1.8:1) consulted in the rheumatology clinic with new manifestations of articular, periarticular, bone, or inflammatory symptoms. The majority of patients consulted for joint pain (93.6%), less frequently low fever, skin rashes, and sicca syndrome were reported (2.1% cases each). The mean duration of symptoms was 9.8±10.5 (range 1-42) weeks, and the time to onset after the diagnosis of COVID-19 was 4.9±4.1 (range 0-12) weeks. In 60.9% of cases, the severity of the COVID-19 disease was mild, 17.4% - moderate, and 21.7% - severe. They were diagnosed: reactive arthritis - 74.4%, Lupus-like syndromes - 6.8%, Sjogren's syndrome - 2.1%, avascular necrosis - 10.6%, rheumatoid arthritis - 4.2% and psoriatic arthritis at onset 2.1% cases. Conclusions. COVID-19 disease can lead to a variety of musculoskeletal manifestations in the time frame following its resolution; therefore, in the presence of joint symptoms or other signs that suggest an autoimmune disease, patients should be referred for a rheumatological check-up.